What it's for (Indications)
- Cefuroxime, marketed under various brand names including Zecef, is a second-generation cephalosporin antibiotic indicated for the treatment of a broad range of bacterial infections caused by susceptible microorganisms.
- Its therapeutic applications include, but are not limited to, respiratory tract infections such as acute exacerbations of chronic bronchitis, pneumonia, and acute bacterial sinusitis.
- It is also effective in treating urinary tract infections, skin and soft tissue infections, uncomplicated gonorrhea, and early Lyme disease.
- Additionally, intravenous cefuroxime is frequently employed for surgical prophylaxis to prevent postoperative infections.
- The selection of cefuroxime for therapy should always be based on susceptibility testing of the causative pathogen, if available, or on empirical therapy guided by local epidemiological data and clinical judgment to ensure appropriate and effective treatment.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of cefuroxime varies significantly depending on the specific infection being treated, the route of administration (oral as cefuroxime axetil or parenteral as cefuroxime sodium), the patient's age, weight, and renal function. For oral administration, common adult dosages range from 250 mg to 500 mg twice daily for 5 to 10 days, or as determined by the prescribing physician. Pediatric oral dosages are typically weight-based, often calculated per kilogram. For parenteral administration, adult doses commonly range from 750 mg to 1.5 g every 8 hours, administered intravenously or intramuscularly, depending on the severity and type of infection. In patients with impaired renal function, dosage adjustments are imperative to prevent drug accumulation and potential adverse effects. It is critical for patients to adhere strictly to the prescribed dosage regimen and complete the full course of therapy, even if symptoms improve, to ensure complete eradication of the infection and minimize the development of antibiotic resistance. |
Safety & Warnings
Common Side Effects
- Cefuroxime, like all medications, can cause a range of side effects, though not everyone experiences them.
- Common adverse reactions primarily involve the gastrointestinal system, including diarrhea, nausea, vomiting, and abdominal discomfort.
- Other frequently reported side effects include headache and dizziness.
- More serious, albeit less common, adverse events encompass hypersensitivity reactions such as skin rashes, urticaria, angioedema, and potentially life-threatening anaphylaxis.
- Hematological effects like eosinophilia, transient decreases in hemoglobin, neutropenia, and thrombocytopenia have been observed.
- Hepatic enzyme elevations (AST, ALT, alkaline phosphatase) are possible.
- Prolonged use can lead to the overgrowth of non-susceptible organisms, potentially resulting in superinfections or *Clostridioides difficile*-associated diarrhea (CDAD), which can range in severity from mild to severe and even fatal colitis.
- Central nervous system effects such as seizures are rare and typically associated with high doses or impaired renal function.
- Local reactions like pain at the injection site (intramuscular) or phlebitis (intravenous) may also occur, requiring careful administration.
Serious Warnings
- Black Box Warning: Cefuroxime does not carry a formal FDA Black Box Warning. However, several serious warnings and precautions warrant significant attention from healthcare providers and patients. **Serious Warnings:** 1. **Hypersensitivity Reactions:** Severe, potentially life-threatening hypersensitivity reactions, including anaphylaxis, can occur. Patients should be thoroughly questioned about previous allergic reactions to cephalosporins, penicillins, or other beta-lactam antibiotics. Cefuroxime is contraindicated in patients with a history of immediate-type severe hypersensitivity to penicillin or other beta-lactams due to potential cross-reactivity. In the event of an allergic reaction, discontinue cefuroxime immediately and institute appropriate emergency medical treatment. 2. ***Clostridioides difficile*-Associated Diarrhea (CDAD):** *Clostridioides difficile*-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including cefuroxime, and may range in severity from mild diarrhea to fatal colitis. CDAD can occur over two months after the administration of antibacterial agents. It is important to consider this diagnosis in patients who present with diarrhea following antibiotic use. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued, and appropriate fluid, electrolyte, protein supplementation, and antimicrobial therapy against *C. difficile* should be initiated promptly. 3. **Renal Impairment and Neurotoxicity:** Dosage adjustment is essential in patients with impaired renal function to prevent accumulation of cefuroxime, which can lead to adverse effects including neurotoxicity, such as seizures. Careful monitoring of renal function and appropriate dose modification are critical in this patient population to mitigate these risks. 4. **Superinfection:** Prolonged or inappropriate use of cefuroxime may result in the overgrowth of non-susceptible bacteria or fungi, leading to superinfections. Patients should be closely monitored for signs of new infections during therapy, and appropriate measures should be taken if superinfection is suspected or confirmed.
- Patients should be meticulously evaluated for a history of hypersensitivity reactions to cephalosporins, penicillins, or other beta-lactam antibiotics prior to initiating cefuroxime therapy, given the potential for cross-reactivity.
- Severe acute hypersensitivity reactions, including anaphylaxis, can occur and require immediate emergency medical treatment.
- The use of broad-spectrum antibiotics, including cefuroxime, has been associated with the development of *Clostridioides difficile*-associated diarrhea (CDAD), which can range in severity from mild diarrhea to fatal colitis.
- It is crucial to consider this diagnosis in patients presenting with diarrhea during or after antibiotic administration.
- Dosage adjustments are necessary for patients with impaired renal function to prevent drug accumulation and potential neurotoxicity, including seizures.
- Prolonged use of cefuroxime may lead to the overgrowth of non-susceptible organisms, necessitating careful monitoring for superinfections.
- Cefuroxime may interfere with certain laboratory tests, such as causing a false-positive direct Coombs' test, which should be considered in diagnostic evaluations.
- Caution is advised when co-administering with nephrotoxic drugs, as this may increase the risk of renal adverse effects.
How it Works (Mechanism of Action)
Cefuroxime exerts its bactericidal effect by interfering with the synthesis of the bacterial cell wall. As a second-generation cephalosporin antibiotic, it achieves this by binding to specific proteins known as penicillin-binding proteins (PBPs) located within the bacterial cytoplasmic membrane. These PBPs are crucial enzymes involved in the transpeptidation step of peptidoglycan synthesis, a process essential for maintaining the structural integrity and rigidity of the bacterial cell wall. By covalently binding to these PBPs, cefuroxime inactivates them, thereby inhibiting the cross-linking of peptidoglycan strands. This disruption leads to a defective and weakened bacterial cell wall, ultimately resulting in osmotic instability, cell lysis, and bacterial cell death. Cefuroxime's spectrum of activity includes a wide range of Gram-positive and Gram-negative bacteria, offering improved activity against some Gram-negative organisms compared to first-generation cephalosporins, while retaining good activity against many Gram-positive strains, making it effective against a diverse array of bacterial pathogens.